Figure 2From: The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s diseaseMean change from baseline in the Alzheimer’s Disease Assessment Scale – Cognitive Subscale score. Effects of 24-week intake of study product on the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog) in the intent-to-treat cohort. Error bars represent standard errors. P = 0.513 (mixed models for repeated measures).Back to article page